You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Mean (or Median) or Percentage
|
|---|
|
Gender, male rate
|
40%
|
|
Age, years
|
12.91 (SD 2.37)
|
|
BMI, kg/m2
|
20.23 (SD 3.87)
|
|
JIA subtype
|
|
Oligoarticular
|
75%
|
|
Polyarticular
|
16%
|
|
Undifferentiated
|
9%
|
|
Pharmacological treatment
|
|
Follow-up without medication
|
19%
|
|
NSAID only
|
19%
|
|
DMARD (with or without NSAID)
|
62%
|
|
Disease duration, months
|
41.00 (SD 38.05)
|
|
DAS28
|
2.85 (SD 1.23)
|
|
Hip arthritis
|
12.5%
|
|
Knee arthritis
|
28.1%
|
|
Foot/ankle arthritis
|
15.6%
|
|
JADI-A
|
0 (IQR 1) (min 0, max 8)
|
|
LED positivity rate
|
37.5%
|
|
6MWT, m (n: 30)
|
427.76 (SD 107.47)
|
|
CYC-E test duration, min
|
10.46 (SD 4.22)
|
|
CHAQ
|
0.13 (IQR 0, 0.69)
|
|
PedsQL-3A
|
84.37 (SD 13.45)
|
- NSAID non-steroid anti-inflammatory drug, DMARD biologic or conventional disease-modifying anti-rheumatic drug, DAS28 disease activity score 28, JADI-A Juvenile Arthritis Damage Index – Articular, LED lower extremity deformity, 6MWT 6-min walk test, CYC-E cycling exercise, CHAQ Childhood Health Assessment Questionnaire, PedsQL-3A PedsQL 3.0 Arthritis Module
